Matthew G Krebs
Overview
Explore the profile of Matthew G Krebs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
3582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2025 Mar;
16(1):2242.
PMID: 40050276
No abstract available.
2.
Krebs M, Forster M, Majem M, Peguero J, Iams W, Clay T, et al.
JTO Clin Res Rep
. 2024 Oct;
5(11):100725.
PMID: 39403626
Introduction: Eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, triggers antigen-presenting cell and T-cell (CD4 and CD8) activation and helps overcome resistance to programmed cell death protein 1 or...
3.
Frankell A, Dietzen M, Al Bakir M, Lim E, Karasaki T, Ward S, et al.
Nature
. 2024 Jul;
631(8022):E15.
PMID: 38965439
No abstract available.
4.
Tasken K, F Haj Mohammad S, Fagereng G, Falk R, Helland A, Barjesteh van Waalwijk van Doorn-Khosrovani S, et al.
Acta Oncol
. 2024 May;
63:385-391.
PMID: 38779910
Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to...
5.
Conway A, Pearce S, Clipson A, Hill S, Chemi F, Slane-Tan D, et al.
Nat Commun
. 2024 Apr;
15(1):3292.
PMID: 38632274
Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic challenge due to biological heterogeneity and poor responses to standard chemotherapy. Predicting tissue-of-origin (TOO) molecularly could help refine this diagnosis,...
6.
Fan Y, Drilon A, Chiu C, Loong H, Siena S, Krzakowski M, et al.
Clin Lung Cancer
. 2024 Jan;
25(2):e81-e86.e4.
PMID: 38245456
No abstract available.
7.
Drilon A, Camidge D, Lin J, Kim S, Solomon B, Dziadziuszko R, et al.
N Engl J Med
. 2024 Jan;
390(2):118-131.
PMID: 38197815
Background: The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of fusion-positive non-small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial...
8.
Sacher A, LoRusso P, Patel M, Miller Jr W, Garralda E, Forster M, et al.
N Engl J Med
. 2023 Aug;
389(8):710-721.
PMID: 37611121
Background: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. Methods: In a phase 1 study, we evaluated divarasib administered orally once...
9.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2023 Aug;
14(1):4741.
PMID: 37550302
No abstract available.
10.
Coombes R, Howell S, Lord S, Kenny L, Mansi J, Mitri Z, et al.
Nat Commun
. 2023 Jul;
14(1):4444.
PMID: 37488191
Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we...